更新于：2024-12-09
Doxofylline
多索茶碱
更新于：2024-12-09
概要
基本信息
原研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C11H14N4O4 |
InChIKeyHWXIGFIVGWUZAO-UHFFFAOYSA-N |
CAS号69975-86-6 |
关联
30
项与 多索茶碱 相关的临床试验多索茶碱片在健康受试者中餐后状态下的单剂量、随机、开放、四周期、完全重复交叉设计的生物等效性试验
多索茶碱片在健康受试者中餐后状态下的单剂量、随机、开放、四周期、完全重复交叉设计的生物等效性试验
Comparative study of Oral Doxophylline along with Triple drug therapy versus Triple Drug Therapy in Stable Severe Chronic Obstructive Pulmonary Disease Patients A Randomised control Trial. - NIL
100 项与 多索茶碱 相关的临床结果
登录后查看更多信息
100 项与 多索茶碱 相关的转化医学
登录后查看更多信息
100 项与 多索茶碱 相关的专利（医药）
登录后查看更多信息
124
项与 多索茶碱 相关的文献（医药）2025-02-01NEUROCHEMICAL RESEARCH
Doxophylline, a Non-Selective Phosphodiesterase Inhibitor, Protects Against Chronic Fatigue-Induced Neurobehavioral, Biochemical, and Mitochondrial Alterations
Article
作者: Kadian, Monika ; Kumar, Anil ; Sarkar, Ankan ; Jain, Manish ; Sharma, Garima ; Vashishth, Anushka
Chronic fatigue stress (CFS) is a multisystem disorder which exhibits multiple signs of neurological complications like brain fog, cognitive deficits and oxidative stress with no specific treatment. Doxophylline, a non-selective phosphodiesterase inhibitor (PDEI), has anti-inflammatory properties with enhanced blood-brain barrier penetration and tissue specificity. We have evaluated the neuroprotective potential of doxophylline in a murine model of forced swim test (FST) induced CFS and in H2O2 (hydrogen peroxide) induced oxidative stress in PC12 cells. An FST model to induce a state of CFS in mice was induced by forcing them to swim daily for 6 min for 15 days. The drug was administered daily 30 min prior to FST. The immobility period was compared for day 1 and day 15. Animals were sacrificed on day 16 for biochemical, mitochondrial, and histopathological estimations in the brain. Cytotoxicity assay, reactive oxygen species (ROS) and nuclear morphology determination were carried out in PC12 cells. A significant increase in immobility has been observed on the 15th day in CFS-induced mice compared to doxophylline treated group. Neurobehavioral studies revealed hypo locomotion, anxiety, motor incoordination, and memory deficit. Biochemical analysis showed a significant change in oxidative stress markers (superoxide dismutase (SOD), reduced glutathione (GSH), catalase, lipid peroxidation (LPO) and nitrite levels) and acetylcholinesterase enzyme activity (AChE) in brain homogenates. Doxophylline pre-treatment protects against these impairments. In PC12 cell lines, doxophylline exhibits alleviation against H2O2-induced oxidative stress, intracellular ROS generation, and changes in nuclear morphology. Doxophylline could be promising and possess therapeutic potential in CFS treatment. Further research is needed to test if doxophylline can be repurposed for neurological disorders.
2024-10-01SCIENCE PROGRESS
Development of a rapid method for the simultaneous determination of aminophylline, doxofylline, bromhexine, and ambroxol by HPLC
Article
作者: Feng, Yunxia ; Shi, Ming ; Chen, Fuchao ; Meng, Xia ; Fang, Baoxia
Introduction: Antitussive and expectorant drugs such as aminophylline (APL), doxofylline (DXL), bromhexine hydrochloride (BXH), and ambroxol hydrochloride (AXH), either individually or in combination, are widely used in the prevention and treatment of respiratory diseases. The study aimed to establish a high-performance liquid chromatography (HPLC) method for the simultaneous determination of these four drugs and to investigate their stability in 0.9% sodium chloride injection or 5% glucose injection over 48 hours. Methods: An InertSustain C18 column (150 mm × 4.6 mm, 5 μm) was used. The mobile phase consisted of acetonitrile and 50 mmol·L−1 potassium dihydrogen phosphate solution (pH 4.0) with gradient elution. The flow rate was 0.8 mL·min−1, and the column temperature was maintained at 30°C. The stability of APL, DXL, BXH, and AXH in 0.9% sodium chloride and 5% glucose injections over 48 h was determined using HPLC. Results: APL, DXL, BXH, and AXH showed good linearity within the ranges of 0.01 to 0.20, 0.003–0.06, 0.015–0.30, and 0.016–0.16 mg·mL−1, respectively (r > 0.999). The intraday and interday relative standard deviations were <2%, with recovery rates between 98.4% and 102.2%. The four drugs remained colorless and clear in infusion mixtures. The pH value fluctuated within ±0.3 over 48 hours, and the relative percentage content of the drugs ranged from 95.0% to 105.0%. Conclusion: The established HPLC method is simple, reliable, and stable, allowing for the simultaneous determination of the four antitussive and expectorant drugs. APL, DXL, BXH, and AXH were stable within 48 hours when mixed with 0.9% sodium chloride and 5% glucose injections.
2024-06-02The Journal of asthma : official journal of the Association for the Care of Asthma
Doxofylline as a steroid-sparing treatment in Mexican children with asthma
Article
作者: González-Díaz, Sandra Nora ; Macouzet-Sánchez, Carlos ; Ansotegui, Ignacio J. ; Acuña-Ortega, Natalhie ; de la Cruz-de la Cruz, Carlos
OBJECTIVE:
The aim of this pilot study was to assess the efficacy of doxofylline as an ICS-sparing agent in the treatment of Mexican children with asthma.
METHODS:
10-week, open-label, crossover, pilot study, we examined the steroid-sparing effect of doxofylline in Mexican children with asthma. Patients aged 6-16 years treated with inhaled corticosteroids (ICS) for at least 8 wk before enrollment were divided randomly into two groups at the baseline visit. Group A (n = 31) received doxofylline (18 mg/kg/day) plus standard-dose budesonide (D + SDB) for the first 4-week period followed by doxofylline plus reduced-dose budesonide (D + RDB) for the second 4-week period. Group B (n = 30) received D + RDB followed by D + SDB. Clinical outcomes assessed included lung function (forced expiratory volume; in 1 s, FEV1), fractional exhaled nitric oxide (FeNO), asthma control, number of exacerbations and use of rescue medication (salbutamol).
RESULTS:
It was shown that combined use of doxofylline and ICS may allow children with asthma to reduce their daily dose of ICS while maintaining lung function and improving asthma control (p = 0.008). There were few asthma exacerbations and only one patient required treatment with systemic corticosteroids. Rescue medication use decreased significantly in patients receiving D + SDB during the first 4-week period.
CONCLUSIONS:
Our results suggest that doxofylline may be a steroid-sparing treatment in asthma, but longer-term, controlled studies are needed to confirm these observations.
100 项与 多索茶碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 意大利 | 2001-12-10 | |
| 哮喘 | 意大利 | - | 1988-10-01 |
| 慢性支气管炎 | 意大利 | - | 1988-10-01 |
| 慢性阻塞性肺疾病 | 意大利 | - | 1988-10-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 支气管扩张 | 临床前 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 227 | Doxofylline 400 mg t.i.d | 網齋醖築選網糧願蓋艱(憲艱襯願鬱糧鑰築襯願) = 10% 齋衊範壓夢遞窪積艱淵 (鏇壓膚鑰顧醖獵膚糧鑰 ) 更多 | 积极 | 2019-09-28 | ||
N/A | - | 積觸鬱窪鑰鏇夢醖淵膚(廠衊壓衊夢廠願夢製夢) = 鹽襯窪築廠鏇夢餘壓鏇 構網遞積獵鹹鑰選獵糧 (蓋鑰醖夢醖簾憲簾夢鑰 ) | - | 2014-09-01 | |||
積觸鬱窪鑰鏇夢醖淵膚(廠衊壓衊夢廠願夢製夢) = 願廠糧鹹膚獵壓蓋鹹襯 構網遞積獵鹹鑰選獵糧 (蓋鑰醖夢醖簾憲簾夢鑰 ) | |||||||
N/A | 30 | Doxofylline 400 mg bid + inhaled bronchodilators | 艱繭襯齋繭憲蓋觸築衊(襯觸膚繭壓遞鹹餘蓋餘) = 鏇遞願糧鏇鏇繭鏇構築 淵願廠鏇顧醖襯願繭鹹 (淵網壓獵衊窪鬱積鏇鬱 ) | 积极 | 2011-09-01 | ||
inhaled bronchodilators only | 艱繭襯齋繭憲蓋觸築衊(襯觸膚繭壓遞鹹餘蓋餘) = 廠壓醖憲鹽鏇觸簾窪蓋 淵願廠鏇顧醖襯願繭鹹 (淵網壓獵衊窪鬱積鏇鬱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用